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Abstract
Interleukin-1 (IL-1) mediates many components ofgeneralized
host response to injury and mayalsocontribute to local vascular
pathology during immune or inflammatory responses. Because
alteredfunction ofsmoothmusclecells(SMC)accompanies cer-
tain vascular diseases, wetested whether SMCthemselves might
produce this hormone. Unstimulated SMC contain little or no
IL-i mRNA. However, exposure to bacterial endotoxin caused
accumulation ofIL-1 mRNA inSMCcultured from human ves-
sels. Endotoxin maximally increasedIL-ift mRNA in SMCafter
4-6 h. The lowest effective concentration of endotoxin was 10
pg/ml. 10 ng/ml produced maximal increases in IL-iS mRNA.
Interleukin-la mRNA was detected when SMC were incubated
with endotoxin under "superinduction" conditions with cyclo-
heximide. Endotoxin-stimulated SMCalso released biologically
functional IL-1, measured as thymocyte costimulation activity
inhibitable byanti-IL-i antibody. Thus, humanSMCcanexpress
IL-ift and IL-ia genes, or very similar ones, and secrete bio-
logically active product in response to a pathological stimulus.
Endogenous local production of this inflammatory mediator by
the blood vessel wall's major cell type could play an important
early role in the pathogenesis ofvasculitis and arteriosclerosis.
Introduction
It is increasingly apparent that the blood vessel is not a passive
conduit, but acomplex organcomposed ofhighly differentiated
cellswithspecialized functionsthatplayimportantrolesinhealth
and disease. The endothelial cell that lines the luminal surface
ofthe vessel wall has recently received much attention in this
regard. Blood-borne signals can modulate several important
vascular endothelial cell functions related to thrombosis, inter-
action with leukocytes, and immune competence (1-7). Endo-
thelial cells can also secrete substances that influence the con-
tractile orgrowthpropertiesofsmooth muscle cells(SMC)' that
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1. Abbreviations used in thispaper: Ia, I-region-associated; IL-l, inter-
leukin 1; kb, kilobase; PHA, phytohemagglutinin; pI, isoelectric points;
SMC, smooth muscle cell.
comprise the tunica media of the vessel (8-10). Although the
vascularSMCisby farthe mostnumerous celltype inthevessel
wall, itsrepertoire ofinducible responses hasreceived very little
attention. The SMC isgenerally regarded asatarget forsecretory
products of endothelial cells, platelets, and leukocytes, rather
than as a source ofsignalsthat control the function ofother cell
types (10).
There is some evidence that SMCsthemselves may elaborate
mediators involved in the pathogenesis of vascular diseases.
Inbred mice ofthe MRL/lpr strain develop a spontaneous au-
toimmunevasculitis. In contrasttovascularSMCsfrom normal
mice, those from arteries of MRL/lpr mice express I-region-
associated (Ia) antigens and release an interleukin 1-like thy-
mocyteactivating activity(11). These alteredimmune functions
ofvascularSMCsprobablycontributetothelocalizedpathology
in these mice with genetically determined vasculitis.
Interleukin 1 (IL-1), formerly thought to be produced pri-
marily by cells ofthe monocyte/macrophage lineage, mediates
several key components ofsystemic acute phase response (12-
14). Certain biological properties ofIL-l, such as its abilities to
act as achemoattractant anddegranulating agent and to induce
synthesisofseveralproteins, includingcollagen andproteinases,
supporttheconceptthatIL-l isalsoinvolvedinthedevelopment
oflocal lesions associated with tissue injury (e.g., synovitis, he-
patic or pulmonary fibrosis). In the context ofthe blood vessel,
IL-I can induce several pathogenic functions of vascular en-
dothelial cells, such as synthesis ofatissue-factor-like procoag-
ulant activity and increased leukocyte adhesion (2-4).
Secretion ofIL-l by SMCs themselves might be very im-
portant not only in the vasculitides, but in the early stages of
atherogenesis as well. Thecapacity ofhuman vascular SMCs to
produce IL-1 activity has not yet been investigated. We report
here studies ofthe regulation ofIL-I geneexpression in passaged
primary cultures ofvascular SMCsobtained from human adults.
Theseexperiments identifythiscelltype as anunexpected source
ofthis important mediator that may play a significant role in
vascular pathology.
Methods
Cellpreparations andculture. Human SMCs were grown from explants
or enzymatic digests of surgical specimens of aorta or from trimmed
portionsofthetunicamediaofsaphenousveinsafterenzymaticremoval
ofendothelial cells(15, 16). The useofexcessportions ofhuman vascular
tissue obtained at surgery was approved by the Human Investigation
Review Committee ofthe New England Medical Center. Cell cultures
prepared inthis mannerexhibittypical morphology and"hill and valley"
growth pattern ofcultured vascular SMCs (17). These cells were main-
tained in Dulbecco's modified Eagle's medium (Irvine Scientific, Santa
Ana, CA) buffered with Hepes (25 mM), and supplemented with fetal
bovine serum (10%; HyClone Laboratories, Logan, UT). These cells were
subcultured and harvested as previously described (15, 16). An isolate
ofcell line U-937 derived from human histiocytic lymphoma was pur-
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was maintained and passaged as recommended.
Sources, preparation, and labeling ofDNA probes. There are two
knownhumangenesthatencodemoleculeswithIL-I activity. Theprod-
ucts ofthese genes share only 26% homology ofamino acid sequence
and have distinct isoelectric points (p1; 18, 19). IL-1,6 has a pI of7 and
is the major form expressed by human monocytes (12, 18). IL-la has a
pI of 5 and is the less abundant species of IL-l mRNA in activated
human mononuclear phagocytes (19). The IL-I#l probe used in these
studieswasanAha III-to-Fnud II fragment (1.1 kilobases [kb])ofafull-
length cDNA clone (pCD-418) that encodes the precursor forthis form
(18). For the alpha species of human IL-1 (p1, 5) we used a synthetic
oligonucleotide probe (positions 298-339) that was end-labeled with
gamma [32P]dATP to specific activities >109dpm/1g DNA (19, 20).
The#l-tubulin probe used wasa Pst 1-to-Bam HI fragment(1.3 kb)
ofa rat#l-tubulin cDNA clone (RBT.3) that is expressed constitutively
in manytissues(21). Thisfragmentcontains mostofthetranslated region
of this clone and is highly conserved between species. Plasmids were
isolated chromatographically (22). Thedouble-stranded probes were la-
beled with [32P]dCTP and [32P]dGTP by nick translation to specific ac-
tivities >10' dpm/zg DNA (20).
Extraction ofRNA andNorthern analysis. Total cellular RNA was
isolated by the guandinium isothiocyanate/cesium chloride method (20).
The concentration ofRNA was determined by absorbance at 260 nm.
The ratios of28 S:18 S RNA and ofA 260/A 280 were greater than 2:
1. For Northern hybridization analysis, RNA was electrophoresed into
agarose gels(1.2%)thatcontainedformaldehyde (2.2 M). Aftercapillary
transfer to nylon membranes (Hybond-N, Amersham Corp., Arlington
Heights, IL), the nucleic acids were immobilized by short-wave UV ir-
radiation. We used standard techniques forprehybridization, hybridiza-
tion, and autoradiography (20). Hind III fragments of phage lambda
DNAwereusedassizemarkers. Quantitativeanalysisofautoradiograms
from Northern blots required useofasoftlaserdensitometer (Ultroscan
2202; LKB Instruments, Gaithersburg, MD) equipped with a recording
integrator (HP 3390A). The results presented represent arbitrary units
that correspond to the relative areas under the densitometric peaks.
Biologicaldetermination ofinterleukin-J activity. Biologically func-
tional IL-I was measured as the ability to increase the proliferation of
thymocytesincubatedwith asuboptimal concentration ofthe mitogenic
lectin phytohemagglutinin (PHA). The ability to complement PHA-in-
duced mitogenesis is known as thymocyte costimulation, and is char-
acteristic of IL-I (23, 24). Thymocytes from C3H/HeJ mice (Jackson
Laboratory, Bar Harbor, ME) were incubated for 72 h in RPMI 1640
mediumsupplementedwithfetalcalfserum (10%), PHA(I ug/ml),with
orwithout testspecimens. Tritiatedthymidine(6-7 Ci/mM, 10,Ci/ml)
was added during the last 18 h ofthis incubation, and the radioactivity
incorporated wasdetermined byliquidscintillation spectroscopy. Inter-
leukin-lf produced by recombinant DNA techniques or purified from
human blood monocytes was used as a positive control. Triplicate de-
terminations were performed on each sample, and results are presented
as mean±standard deviation.
Results
Human vascular SMCs express the IL-]# gene in response to
bacterialendotoxin. Human vascular SMCs cultured under the
usualconditions contained little or no messenger RNA (mRNA)
that hybridized with the IL-1,I probe (Fig. 1). Endotoxins ob-
tained from Gram-negative bacteria are potent inducers ofIL-
1 productionbymononuclearphagocytes(12-14). Accordingly,
wetestedwhetherthispathologicstimulus wouldinduceexpres-
Sion ofthe IL-1( gene in adult human aortic SMCs. Bacterial
endotoxin increased the proportion ofIL-1# message in RNA
extracted from these cells in twoindependent experiments (Fig.
1 and data not shown). This phenomenon was also observed in
IL-1p A
Endotoxin - +
13-Tubulin a
Human Aortic
Smooth Muscle Cell
Figure 1. Adult human
aortic SMCs express the
IL-It gene. SMCs iso-
lated by enzyme disso-
ciation from the aorta of
a previously healthy
4 28S I trauma victim (14-yr-
old male) were incu-
bated in the absence (-)
or presence (+) ofE.
coli endotoxin (055:B5;
4 185 S I1O ug/ml; 6 h). Cells of
the human monocytoid
line U-937, known to
produce IL-I, were also
exposed to endotoxin as
+ a positive control and
size marker. RNA was
isolated from the cells,
and Northern analysis
4 28S * (20 jsg RNA per lane)
was performed as de-
scribed in Methods. The
_ positions ofthe 28 S
and 18 S ribosomal sub-
units visualized by ultra-
] violet light are indicated
U937 by the arrowheads in
this and subsequent
northern blots. A shows
a hybridization ofthis blot with a nick-translated IL-SI probe. The IL-
,lmRNA from the endotoxin-stimulated smooth muscle and U-937
cellscomigrate. Analysis ofthis and other Northern blots calibrated
with DNA standards indicated that the size ofthis mRNA was - 1.6
kb. B shows a rehybridization ofthe same Northern blot with the ft-
tubulin probe after removal ofthe IL-I probe. The two transcript sizes
found in these cells are similar to those constitutively expressed in
many other tissues.
cells derived from medial explants of human saphenous vein
(Fig. 2). Thesizeofthetranscript was
- 1.6kb, and this mRNA
speciesmigratedcloselywith IL-I transcriptsextracted from en-
dotoxin-stimulated human monocytes or from U-937 cells(Figs.
1 and 2, and data not shown).
The accumulation of IL-1,8 mRNA in human SMCs de-
pended on the length ofincubation with endotoxin. Exposure
ofhuman saphenous vein SMCs to endotoxin increased IL-I#
message levels substantially afterjust 1 h (Fig. 2). In two inde-
pendent experiments, IL-I# mRNA levels after 24 h ofcontin-
uous exposure to endotoxin were lower than those measured
after 4 or 6 h (Fig. 2 and data not shown). The continuous
presence ofendotoxin was not required for IL1 induction in
these cells. 30 min ofexposure to endotoxin (1 Ag/ml), followed
bywashingandsubsequent incubation withoutendotoxin, pro-
duced a similar increase in IL,1I# mRNA levels 4 h after initial
exposure, asdid incubation forthe entire 4-h period in the con-
tinued presence ofendotoxin (Fig. 3).
The increased expression of the IL-Il3 gene in SMCs also
depended ontheconcentration ofendotoxin. Concentrations as
low as 10 pg/ml increased IL-fl mRNA levels severalfold (Fig.
4). Polymyxin B, anantagonist ofthe actions ofendotoxin me-
diated by the lipid A moiety, inhibited this response (Fig. 4).
This result confirmed thattheability ofendotoxin preparations
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Figure 4. Concentration dependence ofendotoxin induced IL-lI#
expression in human saphenous vein SMCs. Cultures ofhuman sa-
phenous vein SMCs were exposed to the indicated concentrations of
endotoxin (E. coli; 055:B5) for 4 h. A duplicate culture incubated with
the highest concentration tested also contained the endotoxin antago-
nist polymyxin B (PMX B, I Ag/ml). The results are presented in arbi-
trary units derived by quantitative densitometry ofthe autoradiogram
ofa Northern blot hybridized with the IL-I# probe.
Figure 2. Time course ofIL-I# mRNA induction by endotoxin. Sa-
phenous vein SMCs were incubated with endotoxin (E. coil; 055:B5, I
Mg/ml) for the times indicated. RNA was extracted and Northern blot-
ting was performed (see Fig. 1). The two left lanes contain RNA ex-
tracted from U-937 cells (see Fig. 1). or human dermal fibroblasts.
The upper panel shows the results of a hybridization with the IL-DI
probe, the bottom panel shows a rehybridization with the fl-tubulin
probe (see Fig. 1).
to augment levels of IL-1 mRNA was due to the lipopolysac-
charide and notcontaminating material. The ability ofbacterial
lipopolysaccharides to augment IL-l18 gene expression was not
limited to products of one species, serotype, or Gram-negative
organism. Endotoxin from E. coil 011 :B4 (L-2630; Sigma
Chemical Co., St. Louis, MO), Salmonella typhosa (L-6386;
Sigma Chemical Co.) orSalmonella Minnesota (L-6261; Sigma
Chemical Co.)allincreased IL1,Il mRNA contentinSMCs(Fig.
5). The marked increase in IL-1I# gene expression in endotoxin-
stimulated human SMCs was not due to a non-specific effect on
mRNA levels, since rehybridization of a number of Northern
blots with fl-tubulin or a-actin probes showed no consistent
change in the level ofthese mRNAs underthese conditions (Figs.
1, 2, 5 and 6; bottom panels, and data not shown).
Figure 3. Maximal in-
o duction ofIL-, I mRNA
in SMCs does not re-
quire continued pres-
> 1 0 -_ ] ence of endotoxin. Hu-
man saphenous vein
Z-it, ~~~~~~~SMCs were incubated
E with or without endo-
toxin (E. coil; 055:B5, 1
3m i, pg/ml). After exposure
TIME OF EXPOSURE TO ENDOTOXIN to endotoxin for the
times indicated, the cells
were washed in medium containing the endotoxin antagonist poly-
myxin B (10 ,g/ml), and subsequently incubated in medium lacking
endotoxin. After incubation for a total of4 h, RNA was isolated from
each culture, and the amount ofIL-1I, mRNA was determined by
Northern blotting.
Detection ofIL-i alpha mRNA in SMCs "superinduced" in
the presence ofcycloheximide. Under usual conditions, no IL-
la mRNA was detected in SMCs even after incubation with
endotoxin under conditions that readily induced ILH-lI mRNA
(Fig. 6 and data not shown). In SMCs incubated with cyclohex-
imide (10 gg/ml), IL-ljI mRNA increased and IL-la mRNA
was detected (Fig. 6). Simultaneous incubation with cyclohex-
imide and endotoxin increased mRNA forboth ofthese human
IL-I genes substantially (Fig. 6). This briefincubation with cy-
IL-1 A
-28S
D18S
Control E. colt S. typhosa S. Minnesota
Source of Endotexin
0-Tubulin B
-28S
_M
_ P|.
. AM op.
.__I -18S
Figure 5. Various bacterial endotoxins induce IL,lIl mRNA in human
SMCs. Human saphenous vein SMCs were incubated without (Con-
trol), or with endotoxins (I gg/ml) from the three bacterial species in-
dicated for 6 h. Northern analysis and presentation ofthe data are as
in Fig. 1.
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Figure 6. "Superinduction" ofIL-la and IL-1I, mRNA in human vas-
cular SMCs. Human saphenous vein SMC cultures were incubated
without (-), or with (+) cycloheximide (10 gg/ml) for 2 h. After this
2-h preincubation, the cultures were incubated without (-), or with
(+) endotoxin (E. coli; 055:B5, 1 ug/ml) for another 2 h. In the cyclo-
heximide (+) conditions, the cycloheximide was also included in the
test incubation with or without endotoxin. RNA was extracted from
all cultures after incubation for a total duration of4 h (including the
2-h preincubation with or without cycloheximide). Northern analysis
was performed as in Fig. 1. The top panel shows the result ofa hybrid-
ization with the IL- a probe. The middle panel shows a hybridization
ofthe same Northern blot with the IL-I, probe. The bottom panel
shows a third hybridization ofthe same blot with the fl-tubulin probe.
cloheximide did not alterthe viability ofthe cells asdetermined
byphasemicroscopic observation orcause adecline inthe num-
berofcellsharvested forRNAextraction. Thetotal RNAcontent
per cell was likewise unchanged by the 4-h incubation with cy-
cloheximide (data not shown).
BiologicallyactiveIL-I issecretedbyvascularSMCsexposed
to endotoxin. To determine if SMCs stimulated by endotoxin
also produce and secrete functional IL-1, we examined whether
material elaborated by these cells exhibited thymocyte costi-
mulation, a characteristic biological activity ofIL-1. In the ab-
sence ofendotoxin, human saphenous vein or aortic SMCs se-
crete little or no IL- detected bythisassay (Tables I and II, Fig.
7). Medium collected from endotoxin-stimulated SMCs secreted
biological activity that was detected over a range ofconcentra-
tions tested (Table I). Thymocyte costimulation activity released
by stimulated saphenous vein SMCs was partially neutralized
byrabbit antihuman monocyte IL-I antibody diluted 1:100 (Fig.
7, solidbars). The same dilution ofnonimmune serum did not
reducethisactivity(Fig. 7, crosshatchedbars). Inanindependent
experiment, human aortic SMCstreatedwith endotoxin released
thymocytecostimulationactivitythatwascompletelyneutralized
by the anti-IL- antibody (Table II).
Discussion
The vascular SMC is an unexpected and novel source ofIL-1,
an important inflammatory mediator previously thought to be
produced primarily bymononuclear phagocytes. Recently, pro-
0
ENDOTOXIN -
Ll ~
NO ANTISERUM ANTI IL-1 NON-IMMUNE SERUM
Figure 7. Human venous SMCs can secrete biologically active IL-1.
Human saphenous vein SMCs were incubated without (-), or with
endotoxin (E. coli; 055:B5; 1 Ag/ml) for 24 h. The supernatant media
were assayed for thymocyte costimulation activity (see Methods). Data
shown aremean±SD ofthree to six replicate determinations on media
from one culture. The value measured using medium that had not
been exposed to SMCs is shown by the open bar. The stippled bars
show activity measured in the absence ofantibody. The solid bars
show data measured when rabbit antihuman blood monocyte IL-I (1:
100) was included during the thymocyte assay. The cross-hatched bars
show data obtained when this assay was performed in the presence of
nonimmune rabbit serum(1:100).
duction ofIL-I-like activity has been attributed to other cells
thatare notderivedfrombonemarrow(3, 25-30). Forexample,
humankeratinocytescanproduce athymocyte-activatingfactor
thatresemblesIL-1 (25). Astrocytes andoligodendroglia are an-
other potential source ofsuch activity (26). In addition, several
laboratories have observedIL-I-like activity secreted by B lym-
phocytes, epithelial andmesangial cells, and vascularendothelial
cells (3, 7, 27-30). We are unaware ofprevious descriptions of
such activity from human vascular SMCs.
Table L Endotoxin-stimulated Human Aortic
SMCs SecreteBiologicallyActive IL-1
Thymocyte costimulation activity
Concentration -Endotoxin +Endotoxin*
Medium from human 1:2 11,348±2,001 26,761±6,052
aortic SMCs 1:4 9,227±521 20,374±1,823
1:8 7,893±1,479 21,672±2,975
1:16 4,078±3,393 18,445±3,806
MonocyteIL-1t 1 U/ml 28,458±4,295
Data are thymidine incorporation in cpm(mean±SD, n = 3). The
background incorporation induced-by PHA alone in this experiment
was7,809±2,384.
* Medium was conditioned by the SMCs in the presence ofendotoxin
(E. coli,055:B5, 10,ug/ml) for 24 h.
tIL-I purified aspreviously described (24).
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Activity Released byEndotoxin-stimulated
Human Aortic Smooth Muscle Cells (HASMC)
Thymocyte costimulation activity
Concentration -Anii-IL-I +Anti-IL 1*
Medium from HASMC 1:10 5,697±1,600 3,585±361
Medium from
endotoxin-stimulated
HASMCf 1:10 8,079±840 3,214±336
Recombinant IL-Idl 200 ng/ml 24,688±5,863 3,717±128
Data are thymidine incorporation in cpm (mean±SD, n = 3). The
background incorporation induced by PHA alone in this experiment
was 4,021±677.
* Rabbit anti-monocyte-derived IL-I antibody was added at 1:100 di-
lution.
f Endotoxin exposure was to E. coli 055:B5 (10 ,ug/ml) for 24 h.
Incubation ofSMCswithcycloheximide increased thelevels
of IL-lIa and IL-1# mRNA, and accentuated the endotoxin-
induced increases inthese transcripts (Fig. 6). This phenomenon,
known as "superinduction," may be due to increased transcrip-
tionand/orreduced rateofmRNAcatabolism (31, 32). Increased
steady-state IL-1 mRNA levels under conditions that inhibit
protein synthesis is consistent with modulation of IL-1 gene
expression by alabile intracellular protein. The failure to detect
IL- la sequences in SMC RNA in the absence ofcycloheximide
may indicate that, as in the human monocyte, this species of
IL-l is a less abundant form. Dayer et al. recently reported that
activated human blood monocytescontain atleast 50-fold more
mRNA for IL-1I8 than for IL-la (33). The lower steady-state
levels ofIL-la relative to IL-IfB mRNA detected in the SMCs
might also be due to differences in the stability ofthe specific
messages, theefficiencyofdetectionwithprobes, orhybridization
conditions employed. However, the specific activity ofthe end-
labeled IL- la probe was actually substantially higher than that
of the nick-translated IL-lB cDNA probe (see Methods), and
theend-labeled probe readilydetected IL-1a sequences in RNA
isolated from human mononuclear cells exposed to endotoxin
without cycloheximide (data not shown).
The RNA species isolated from SMCs that hybridized with
the IL-1 DNA probes used in this study had similarelectropho-
retic mobility to those found in human blood monocytes and
U-937 cells (18, 19, and Figs. 1 and 2). Furthermore, results of
preliminary Southern analysis of restriction digests of human
genomic DNA show no evidence for multiple IL-lj genes (Or-
dovas, J. M., and P. Libby, unpublished observations). These
observations suggest thatIL-I secretedbyendotoxin-stimulated
SMCs is produced by the same IL-I genes previously cloned
from human monocytes. The results presented here did not ex-
plore the biochemical nature ofIL-1 activity secreted by SMCs.
Preliminary studies indicate that SMC IL-l may differ in mo-
lecular weight and immunoreactivity from fully processed IL-I
secreted by human blood monocytes (Warner, S. J. C., and P.
Libby, unpublished observations). Thus, the posttranslational
modification ofSMC-derived IL- may be distinct. This might
explain why the concentration ofanti-IL-1 antibody tested did
not completely neutralize thymocyte costimulation activity se-
creted by SMCs in all experiments (Fig. 7). However, our data
do not exclude that a product ofa heretofore undescribed IL-I
gene orgenes, or that a tissue-specific mRNA produced by exon
shuffling, could contribute to the biological activity released by
the SMCs.
Our finding that vascular SMCs express IL-1 genes in re-
sponse to a pathological stimulus has several important impli-
cations. Examples ofcommunication between different types of
cell in the blood vessel wall are increasing rapidly. IL-I has pro-
found effects on a number ofimportant functions of vascular
endothelial cells. Under normal conditions vascular endothelial
cells provide the ideal nonthrombogenic lining forblood vessels
(34). When exposed to IL-1, however, these cells express atissue
factor-like procoagulant activity ontheirsurface and couldthus
actually promote local thrombosis at sites ofIL-I release (2, 3,
34). IL-I increases the adhesiveness ofendothelial cells for leu-
kocytes ofall classes tested, including granulocytes and mono-
cytes (4). Exposure to this cytokine also causes a striking shape
change of human endothelial cells in culture, probably due to
reorganization ofthe cytoskeleton (35). IL-I alters the pattern
ofprostanoid synthesis by endothelial cells (36, 37). These and
other activities of IL-l on endothelial cells have already been
confirmed using recombinant IL-la and IL-1# (38, 39).
Because of these manifold effects of IL-I on endothelial
function, the production and secretion ofthis mediator by the
underlying SMCs might provide a novel example ofinteraction
between neighboring celltypesinthe vascular wall. Information
transfer between adjacent cells ofdifferent types has been termed
"paracrine" control (40). Therearealreadyanumberofexamples
of potential paracrine regulation of SMCs by products of en-
dothelial cells (8-10). The presentdata suggest thatinformation
may also flow in the opposite direction, from SMCs to the en-
dothelium.
Studies on the MRL/lpr mouse provide an example ofhow
IL-I production by SMCsmightbeinvolved invasculardisease.
These mice develop a spontaneous autoimmune arteritis, char-
acterized by infiltration of mononuclear cells, followed by cy-
tolytic injury to arterial SMCs. Moyer and Reinisch found that
SMCs isolated from the media ofthese mice expressed Class II
major histocompatibility complex determinants (Ia molecules),
andthus mightfunction asantigen-presenting cells. Inaddition,
they found that SMCs cultured from arteries ofMRL/lpr mice,
but not from congenic C3H mice, secreted IL-I-like biological
activity (11). These studies on vasculitic mice support the po-
tential in vivo relevance ofthe presentobservations on cultured
human vascular SMCs ( 1).
Since the characteristic biological activities ofIL-I include
chemotaxis and activation of granulocytes and T-cells, local
production ofIL-I islikely involved in the pathogenesis ofvas-
cularinflammation inothersituations. Byincreasingtheexpres-
sion ofleukocyte adherence molecules on the surface ofneigh-
boringendothelial-cells, IL-I secretedbySMC couldrecruit leu-
kocytestositesofvascular injury orinflammation (4, 5). Further
secretion ofIL-I and other mediators by these infiltrating leu-
kocytes could amplify the original local signal furnished by IL-
1 from vascular wall cells themselves, and perpetuate the in-
flammatory reaction.
Thepresent studyfocused onbacterialendotoxins asstimuli
that induce IL-1 production by SMCs. Other factors may also
signal theproduction ofthis mediatorbythese cells. Suchstimuli
might include antigen-antibody complexes, mitogens such as
platelet-derived growth factor, oxidized lipoproteins that are
known toinjureSMCs, or evenmechanicalfactorssuch asaltered
1436 P. Libby, J. M. Ordovas, L. K. Birinyi, K. R. Auger, and C. A. Dinarellostress in the blood vessel wall due to local hemodynamic ab-
normalities. Although endotoxins cause lyticinjury to somecul-
tured cells, phase-contrast microscopic examination disclosed
no morphologic sign ofcytotoxicity due to these substances in
the current studies. In addition, levels off3-tubulin and a-actin
mRNAs didnotchangesubstantially inendotoxin-treated SMCs.
Thus, the effect ofendotoxin on IL-I gene expression in human
SMCs did not appear to result from a nonspecific toxic effect.
The results presented here are consistent with the current
concept that cells ofthe blood vessel wall are active participants
in the maintenance ofnormal function and in the pathogenesis
ofvascular diseases. The finding that perturbed vascular SMCs
can produce IL-1 demonstrates that this cell type can provide a
primary stimulus for local inflammatory or immune response
in the blood vessel wall. Although the present dataestablish that
human SMCs can produce IL-l in vitro, further study will be
required to test whether these cells express this gene in vivo
under pathologic conditions, and to determine the range ofbio-
logically relevant inducers ofthis phenomenon.
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